Edition:
United Kingdom

Novelion Therapeutics Inc (NVLN.OQ)

NVLN.OQ on NASDAQ Stock Exchange Global Select Market

3.40USD
20 Jul 2018
Change (% chg)

$-0.02 (-0.58%)
Prev Close
$3.42
Open
$3.49
Day's High
$3.58
Day's Low
$3.31
Volume
21,678
Avg. Vol
25,662
52-wk High
$9.58
52-wk Low
$3.10

Latest Key Developments (Source: Significant Developments)

Novelion Therapeutics Reports Quarterly Net Loss Per Share Of $1.76
Thursday, 10 May 2018 

May 10 (Reuters) - Novelion Therapeutics Inc ::NOVELION THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 REVENUE $27.5 MILLION VERSUS $30 MILLION.QUARTERLY NET LOSS PER SHARE $1.76.  Full Article

Novelion Therapeutics Announces Cost Reduction Plans, Capital Structure Review
Wednesday, 24 Jan 2018 

Jan 24 (Reuters) - Novelion Therapeutics Inc ::NOVELION THERAPEUTICS ANNOUNCES COST REDUCTION PLANS AND CAPITAL STRUCTURE REVIEW.NOVELION THERAPEUTICS -ANNOUNCED COST REDUCTION PLANS AS IT MANAGES CASH RESOURCES, EFFECTS OF DELAY & UNCERTAINTY OF SETTLEMENT OF UNIT WITH DOJ, SEC.NOVELION THERAPEUTICS - IN ADDITION TO WORKFORCE AND OTHER COST REDUCTIONS, PURSUING LICENSING OPPORTUNITIES FOR ITS ZURETINOL DRUG CANDIDATE.  Full Article

Edgepoint Investment Group Reports 10.6 Pct Passive Stake In Novelion Therapeutics
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Novelion Therapeutics Inc ::EDGEPOINT INVESTMENT GROUP INC REPORTS 10.6 PERCENT PASSIVE STAKE IN NOVELION THERAPEUTICS INC AS OF NOVEMBER 30 - SEC FILING.  Full Article

Novelion Therapeutics Appoints Michael Price As CFO
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Novelion Therapeutics Inc ::NOVELION THERAPEUTICS APPOINTS MICHAEL PRICE AS SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER.NOVELION THERAPEUTICS INC - ‍GREGORY PERRY HAS RESIGNED AS CFO TO PURSUE OTHER OPPORTUNITIES, AND WILL REMAIN WITH COMPANY UNTIL DECEMBER 31, 2017​.NOVELION THERAPEUTICS INC - ‍APPOINTS MICHAEL PRICE AS SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, EFFECTIVE DECEMBER 4, 2017​.  Full Article

Novelion Therapeutics provides update on agreement between Aegerion Pharma and U.S. Department of Justice
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Novelion Therapeutics Inc :Novelion Therapeutics provides update on agreement between Aegerion Pharmaceuticals and U.S. Department of Justice.Novelion Therapeutics - ‍district judge William Young rejected Aegerion Pharmaceuticals' amended criminal plea agreement which was negotiated with U.S. DOJ.Novelion Therapeutics Inc - ‍company, in consultation with its outside counsel, is currently evaluating its options and next steps​.  Full Article

Novelion Therapeutics says CEO resigns, posts Q3 results
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Novelion Therapeutics Inc :Novelion Therapeutics reports third quarter 2017 financial results and announces leadership change.Sees FY 2017 revenue $135 million to $145 million.Q3 revenue $28.7 million.Novelion Therapeutics Inc - ‍Company reiterates FY 2017 guidance for total net revenues of $135-$145 million​.Novelion Therapeutics Inc - ‍Chief Executive Officer Mary Szela has resigned for personal reasons, effective immediately​.Novelion Therapeutics Inc - ‍Board announced creation of an interim office of chief executive officer​.Qtrly loss per share $2.67 ‍​.Novelion Therapeutics Inc - ‍Continues to anticipate EMA approval for Metreleptin​ in first half of 2018.  Full Article

Morgan Stanley reports 5.2 pct passive stake in Novelion Therapeutics
Friday, 22 Sep 2017 

Sept 22 (Reuters) - Morgan Stanley :Morgan Stanley reports 5.2 percent passive stake in Novelion Therapeutics Inc as of Sept 12, 2017 - SEC filing.  Full Article

Qlt reports Q3 loss per share $0.11
Tuesday, 1 Nov 2016 

Qlt Inc - : Says operating loss for Q3 of 2016 was $6.0 million, compared to $2.8 million for same period in 2015 . Says net loss per common share was $0.11 in Q3 of 2016, . Says continues its phase III pivotal trial start-up activities to test safety and efficacy of its drug product, qlt091001 . Says is currently exploring potential of submitting to fda a request for a rare pediatric disease designation of qlt091001. . Qlt announces third quarter 2016 results .Q3 loss per share $0.11.  Full Article

QLT Q2 loss per share $0.10
Tuesday, 9 Aug 2016 

Qlt Inc : Q2 loss per share $0.10 . Qlt announces second quarter 2016 results .Says qlt plans to change its name upon closing of the merger with aegerion to novelion therapeutics inc..  Full Article

Former Aegerion sales rep charged with defrauding U.S. insurers

NEW YORK, May 15 A former Aegerion Pharmaceuticals Inc sales representative was arrested Tuesday on charges that he defrauded insurance companies into paying for the company's expensive cholesterol drug.